Evotec SE (NASDAQ:EVO - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $5.02, but opened at $5.22. Evotec shares last traded at $5.25, with a volume of 79,727 shares traded.
Analyst Ratings Changes
EVO has been the subject of a number of research reports. Royal Bank of Canada upgraded Evotec from a "sector perform" rating to an "outperform" rating in a research note on Thursday, January 18th. Deutsche Bank Aktiengesellschaft upgraded Evotec from a "hold" rating to a "buy" rating in a research note on Friday, April 12th. Finally, HC Wainwright reduced their price objective on Evotec from $14.00 to $11.00 and set a "buy" rating for the company in a research note on Thursday.
View Our Latest Report on Evotec
Evotec Stock Up 3.6 %
The stock has a 50 day simple moving average of $7.20 and a two-hundred day simple moving average of $8.58.
Institutional Investors Weigh In On Evotec
Several large investors have recently modified their holdings of the stock. Quadrant Capital Group LLC acquired a new stake in Evotec in the fourth quarter valued at $25,000. Optiver Holding B.V. grew its holdings in Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company's stock valued at $945,000 after purchasing an additional 69,936 shares during the last quarter. Finally, Mubadala Investment Co PJSC acquired a new stake in Evotec in the fourth quarter valued at $53,931,000. Hedge funds and other institutional investors own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
